TARC After alloSCT in Hodgkin's Lymphoma

N/ACompletedNCT02069639

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano22 enrolled

Overview

Relapsed and refractory Hodgkin's lymphoma (HL) patients may experience long-term survival after allogeneic transplant (alloSCT), but disease recurrence represents the main cause of treatment failure. PET (positron-emission tomography) -positive patients after alloSCT have a dismal outcome. Serum TARC (thymus and activation-regulated chemokine) is produced by Reed-Sternberg cells and may be a marker of disease. Our study was aimed at assessing whether TARC levels after alloSCT were correlated to disease status and whether TARC monitoring could increase the ability to predict relapse.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation

Interventions

no treatmentOTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Hodgkin's lymphoma patients who underwent an alloSCT at Fondazione IRCCS Istituto Nazionale dei Tumori and who were monitored by PET and TARC before and after alloSCT from 2009 Exclusion Criteria: * Hodgkin's lymphoma patients who underwent an alloSCT who were not monitored by PET or/and TARC

Outcomes

Primary Outcomes

Correlation between disease status and serum TARC level

Serum TARC level was measured before alloSCT in Hodgkin's lymphoma patients and after alloSCT. The median time interval after alloSCT was 47 days. PFS was estimated at one year based on TARC value.

Time frame: One year after transplant

Secondary Outcomes

The correlation between TARC levels and PET results after alloSCT

We selected TARC values done on the days of PET to assess a cut-off value of TARC that was correlated to a positive or negative PET

Time frame: Before alloSCT, monthly during the first 6 months after alloSCT and every 2 months until 2 years of follow-up, then at the time of clinical check-up (usually every 6 months)